JGC
NXTC icon

J. Goldman & Co’s NextCure NXTC Stock Holding History

J. Goldman & Co’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-512
Closed -$228K – 318
2020
Q1 		$228K Sell
512
-30
-6% -$16K 0.03% 208
2019
Q4 		$366K Sell
542
-114
-17% -$57.2K 0.03% 228
2019
Q3 		$243K Buy
+656
New +$213K 0.02% 256

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

J. Goldman & Co's NXTC Position: Q2 2020 in Review

J. Goldman & Co sold out of NextCure (NXTC) in Q2 2020, closing a stake of 512 shares — an estimated $228K sold.

J. Goldman & Co first reported a position in NXTC in Q3 2019 and held it in 3 quarters. The position peaked at $366K in Q4 2019. 88 funds tracked by Wall St. Rank hold NXTC as of Q2 2020.

  • J. Goldman & Co reported no remaining NextCure position as of Q2 2020 after selling out during the quarter.
  • J. Goldman & Co sold 512 NextCure shares in Q2 2020, an estimated $228K.
  • J. Goldman & Co first reported a position in NextCure in Q3 2019 and held it in 3 quarters.
  • J. Goldman & Co's NextCure position peaked at $366K in Q4 2019.
  • 88 funds tracked by Wall St. Rank held NextCure as of Q2 2020.

Based on J. Goldman & Co's 13F filing for Q2 2020, filed 14 Aug 2020.